Could a tau vaccine slow Alzheimer's? new trial aims to find out.
NCT ID NCT07167966
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 30 times
Summary
This phase 2 trial tests whether AADvac1, a vaccine-like therapy targeting tau protein, alone or with donanemab, can reduce tau buildup in the brain and slow Alzheimer's progression. About 450 adults aged 50-80 with early Alzheimer's will participate. The goal is to see if this approach is safe and effective compared to donanemab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.